BEGIN:VCALENDAR
VERSION:2.0
PRODID:-// - ECPv6.6.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.biomed.cas.cz
X-WR-CALDESC:Akce na 
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Prague
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Prague:20250423T150000
DTEND;TZID=Europe/Prague:20250423T160000
DTSTAMP:20260421T162152
CREATED:20250416T064325Z
LAST-MODIFIED:20250416T064325Z
UID:2353-1745420400-1745424000@www.biomed.cas.cz
SUMMARY:Seminář Irena Adkins\, Ph.D.
DESCRIPTION:“Preclinical development of IL-15-based immunocytokine SOT201 and antibody-drug conjugate SOT106 for treatment of solid tumors” \nSOT201 is a novel cis-acting immunocytokine consisting of an antibody against PD-1 genetically fused to a sushi+ domain of IL-15Ra and IL-15 mutein. SOT201 targets PD-1+ TILs with a balanced cytokine potency to revive exhausted T cells in tumor microenvironment. SOT201 is currently being evaluated in Phase I clinical study VICTORIA-01 (NCT06163391) in metastatic advanced cancer patients.SOT106 is a novel antibody-drug conjugate (ADC) targeting LRRC15\, comprised of a proprietary humanized monoclonal antibody conjugated to monomethyl auristatin E (MMAE) via a beta-glucuronidase (GUSB) cleavable linker. SOT106 anti-tumor efficacy was confirmed in soft tissue sarcoma and pediatric osteosarcoma models with moderate to low LRRC15 expression supporting its clinical development as a novel therapy for sarcomas. Combined with its superior performance over a clinical benchmark ADC\, these results underscore the potential of SOT106 as a best-in-class targeted treatment for these challenging malignancies.
URL:https://www.biomed.cas.cz/event/seminar-irena-adkins-ph-d/
LOCATION:Posluchárna Milana Haška / Milan Hašek Auditorium
ORGANIZER;CN="%C3%9AMG":MAILTO:leona.krausova@img.cas.cz
END:VEVENT
END:VCALENDAR